

January 23, 2023

Dystrogen Therapeutics Corp Announces Presentation of Abstracts at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

Dystrogen Therapeutics Corp, a clinical stage chimeric cell therapy company focused on neuromuscular diseases, announced today that its abstracts have been accepted for presentation at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference, taking place from March 19th to 22nd in Dallas, Texas. The conference will feature the latest research and developments in the field of muscular dystrophy and related disorders.

Dystrogen Therapeutics Corp is currently testing its Dystrophic Expressing Chimeric (DEC) cell therapy, called DT-DEC01, for the treatment of Duchenne Muscular Dystrophy (DMD), a rare and progressive muscle disorder that affects one in every 3,500 male births worldwide.

The accepted abstracts include:

- "Assessment of Preliminary Safety and Efficacy of DT-DEC01 Therapy at 12-months after administration to in Duchenne Muscular Dystrophy Patients"
- "Electromyography as an Efficacy Biomarker with Improvement in Motor Unit Potentials after DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients"
- "Prevalence of Anti-HLA Antibodies in Duchenne Muscular Dystrophy Patients at Screening Visit and After Intra-bone Administration of DT-DEC01 Therapy"

The company's abstracts will provide insight into the safety and efficacy of DT-DEC01 therapy in DMD patients, as well as the potential of electromyography as an efficacy biomarker. *"We are thrilled to have our abstracts accepted for presentation at this prestigious conference,"* said Dr. Maria Siemionow, MD, PhD CSO of Dystrogen Therapeutics Corp. *"We believe that our DEC cell therapy has the potential to make an impact in the treatment of Duchenne Muscular Dystrophy and we look forward to sharing our research and findings with the scientific community."*

Dystrogen Therapeutics Corp is committed to advancing the field of cell therapy for neuromuscular diseases and continues to work towards the development of innovative treatments for those affected by DMD and other neuromuscular disorders.

The Muscular Dystrophy Association Clinical & Scientific Conference is the premier meeting for the latest research and developments in the field of muscular dystrophy and related disorders. The conference is attended by leading researchers, clinicians, and healthcare professionals from around the world.